GT Biopharma, Inc. (GTBP) vs Intensity Therapeutics Inc. (INTS)

GT Biopharma, Inc. and Intensity Therapeutics Inc. are both Biotechnology companies. GT Biopharma, Inc. and Intensity Therapeutics Inc. are of similar size ($12.7M and $12.3M). Across the 10 metrics below, Intensity Therapeutics Inc. leads on 6 and GT Biopharma, Inc. on 4.

Valuation

Metric GTBP INTS Biotechnology median
P/E n/m n/m 7.88
P/S 178.31 n/m 11.47
P/B 3.00 1.13 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 96.13 n/m 10.73
Earnings yield (2,140.78%) (44.24%) (28.84%)
Free cash flow yield (133.29%) (85.91%) (23.03%)

Profitability

Metric GTBP INTS Biotechnology median
Gross margin 41.67% 0.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity 102.03% (195.88%) (57.72%)
Return on assets (176.27%) (139.85%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric GTBP INTS Biotechnology median
Revenue growth (TTM) (76.19%) — 5.64%
EPS growth (last fiscal year) 3.75% 70.74% —
Revenue growth, 5-year CAGR 19.67% — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric GTBP INTS Biotechnology median
Debt to equity 0.00 0.01 0.00
Current ratio 2.61 5.00 4.73
Net debt to EBITDA 0.56 0.99 0.96

Dividend

Metric GTBP INTS Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 — 0.00

Size

Metric GTBP INTS Biotechnology median
Market cap 12.32m 12.70m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack